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Age-related macular degeneration (AMD), a 
progressive chronic disease of the central retina, is a 
major cause of blindness worldwide [1]. The prevalence 
of AMD is likely to increase as a consequence of the 
exponential increase in the aging population, and the 
projected number of people with AMD in 2040 is 
around 288 million [2]. Therefore, AMD will be a major 




The precise pathogenesis is still poorly understood. It is 
generally accepted that AMD is the result of a complex 
interaction between genetic and environmental factors 
[3]. 
 
Several risk factors involved in the pathogenesis of 
AMD have been described, including genetic 
predisposition, age, and other modifiable factors such as 
smoking, light and ultraviolet (UV) exposure, dietary 
factors, and hypertension, which may influence the 
molecular mechanisms or cellular processes involved in 
development of the disease. 























In  order  to  investigate  the  influence  of  season  and month  of  birth  on  the  risk  of  neovascular  age‐related
macular degeneration (n‐AMD)  in Italy, we evaluated the month birth and sex of all patients, recorded  in the
anti‐vascular  endothelial  growth  factor  (VEGF)  monitoring  registry  of  the  Italian  Medicines  Agency,  born
between 1925–1944, who  received  intravitreal anti‐VEGF  injections  for n‐AMD between  January 1, 2013 and
July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute
of  Statistics, were used  to  calculate  the  expected number of n‐AMD  cases. Overall, 45,845 patients  (19,207
men,  26,638  women)  received  intravitreal  anti‐VEGF  for  n‐AMD;  in  the  same  years,  20,140,426  people
(10,334,262 male, 9,806,164 female) were born in Italy. Comparing the observed number of n‐AMD cases with
the expected number of n‐ AMD cases  in each season, we  found that the season‐specific risk  for n‐AMD was
2.5% higher for those born in summer (OR=1.03, Bonferroni‐corrected P=0.008) and 3% lower for those born in
winter (OR=0.96, Bonferroni‐corrected P=0.0004). When considering the month of birth, the risk of n‐AMD was
5.9%  lower  for  people  born  in  January  (OR=0.93,  Bonferroni‐corrected  P=0.0012).  The  factors  causing  such
differences should be determined. 
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It is well established that the prevalence and incidence 
of many diseases are related to the month or season of 
birth [4-8]. There is increasing evidence that 
environmental factors in prenatal and early postnatal 
life can have significant effect on the development of 
various diseases later in adulthood. According to the 
“fetal origins hypothesis” of the developmental origins 
of the diseases, the susceptibility to many chronic 
diseases is determined in utero and has a lasting effect 
on the disease process [9]. 
 
No study has investigated whether there is an 
association between the season or month of birth and 
the risk of AMD. The aim of this study was to examine 
whether the month or season of birth is related to the 




Overall, in Italy, 60,818 patients received intravitreal 
injections of anti- vascular endothelial growth factor 
(VEGF) for n-AMD from January 1, 2013 to July 29, 
2015. Consecutive years having at least 1000 
individuals treated were found during the span 1925 to 
1944 (included). A total of 46,826 patients born in these 
years were treated with anti-VEGF; after excluding 981 
patients born outside Italy, a final sample of 45,845 
patients (19,207 men and 26,638 women) who were 



























n-AMD was obtained. In the same years, 20,140,426 
people were born in Italy (10,334,262 males and 
9,806,164 females) and were included in the analysis. 
Figure 1 shows the observed cases and the expected cases 
of n-AMD by month. In the analysis of the season-
specific risk of n-AMD, we compared the number of 
people with n-AMD born in each season with that in the 
general population. The risk of n-AMD was 2.5% higher 
for people born in summer (OR = 1.03; [95% CI, 1.01–
1.06]; χ2 = 3.057, P = 0.002; Bonferroni corrected P = 
0.008) and 3% lower for those born in winter (OR = 0.96 
([95% CI, 0.94–0.98]; χ2 4.03, P = 0.0001; Bonferroni 
corrected P = 0.0004) (Table 1 and Fig. 2). 
 
When we considered the month of birth, the risk of n-
AMD was 5.9% lower for people born in January (OR = 
0.93 [95% CI, 0.91–0.96); χ2 = 4.20, P = 0.0001, 
Bonferroni corrected P = 0.0012) (Table 2 and Fig. 3). 
The results of the subgroup analysis are shown in Tables 
1 and 2, and Figures 4 and 5. In women, the risk of n-
AMD was 2.9% higher for those born in summer (OR = 
1.04 [95% CI, 1.01–1.07); χ2 = 2.68, P = 0.006, 
Bonferroni corrected P = 0.024) and 3.2% lower for 
those born in winter (OR = 0.95 [95% CI, 0.93–0.98); χ2 
= 3.29, P = 0.001, Bonferroni corrected P = 0.004). In 
women, no significant differences were found between 
different months after Bonferroni correction. In men, no 






























Figure 1. Pooled analysis of observed/expected births  in people with neovascular AMD  in  Italy between 1925 and
1944 (n = 45845) with 95% confidence intervals. 










































































































 All borns Observed n-AMD cases Expected n-AMD cases OR, 95 CI, p 
 male female all male female all male female all male female all 



































Total 10334262 9806164 20140426 19207 26638 45845 19207 26638 45845    
p (Bonferroni correction) 
 
1 p=0.168 3 p=0.004  5 p=0.0004  
2 p=0.120  4 p=0.024  6  p=0.188  
    7 p=0.008  
 
Figure  2. Odds  ratios  for  people with  neovascular  AMD  being  born  in  different
seasons  in Italy between 1925 and 1944 (n = 45845) with 95% confidence intervals. 
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DISCUSSION 
 
In this study, we analyzed the month of birth in the 
years 1925 to 1944 of patients with n- AMD who were 
treated with intravitreal anti-VEGF injections in Italy. 
We found a seasonal variation: the number of people 
who developed n-AMD was higher than expected in 
summer, and lower in winter. 
 
Several diseases exhibit an effect of birth month or birth 
season on the incidence.[4-8] A meta-analysis of studies 













































born in April and May and lower risk in those born in 
October and November, as well as a relationship 
between risk and latitude [6]. Similar trends have been 
reported for other immune-mediated diseases. A large 
study of people with type 1 diabetes in the USA found 
that the relative percentage of observed to expected 
births was lower in November–February and higher in 
April–July. This effect was seen in both men and 
women but was evident only in regions in the northern 
latitudes, which suggested a role of factors related to 

















































 All borns Observed n-AMD cases Expected n-AMD cases OR, 95 CI, p 
 male female all male female all male female all male female all 














































































































total 10334262 9806164 20140426 19207 26638 45845 19207 26638 45845    
p (Bonferroni correction) 
 
1 p=0.06 3 p=0.096 5 p=0.0012 
2 p=0.54 4 p=0.144 6 p=0.156 
  7 p=0.468 
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A national study in the UK showed that the distribution 
of births of patients who developed an immune-
mediated disease (e.g., multiple sclerosis, rheumatoid 
arthritis, ulcerative colitis, or systemic lupus 
erythematosus) differed significantly from that of the 
general population. The peak of births for those who 
developed one of these diseases occurred in April and a 
trough in October, and the risk correlated inversely with 
predicted second-trimester UVB exposure and third-
trimester vitamin D status [7]. 
 
Several seasonal factors acting during pregnancy and 
the perinatal period have been proposed to explain these 
data, including infections, dietary factors (e.g., low 
intake of antioxidants in winter), and vitamin D 
deficiency through lack of sun exposure during 
pregnancy.[8]. This latter plays a significant role, since 
increased serum vitamin D concentration is associated 
with a decreased risk of multiple sclerosis [10,11], and 
vitamin D supplementation during the first year of life 
is associated with a significantly decreased risk of type 
1 diabetes [12]. 
 
The biologically active form of vitamin D is generated 
in the skin during exposure to UV radiation from 
sunlight, and its levels follow a seasonal distribution. In 
the Unites States, a study of more than 3 million people 
reported a peak of 25-hydroxyvitamin D (25(OH)D) 



























young women in Italy, the serum concentration in 
summer was reported to be twice that in winter (120 
nmol/l in July vs 60 nmol/l in February) [14]. During 
pregnancy, when a higher amount of vitamin D is 
required, many pregnant women can develop a vitamin 
D deficiency. In Ireland, a higher prevalence of vitamin 
D deficiency (25(OH)D <27.5 nmol/l) was observed in 
pregnant than in nonpregnant women, both in spring 
(44% vs. 18%) and in winter (35% vs 29%) [15]. 
Newborns can have lower vitamin D levels than their 
mothers. In the USA, in winter and spring, a vitamin D 
deficiency (25(OH)D <37 nmol/l) was found in 5% of 
new mothers and in 9.7% of their newborns [16]. In 
Italy, low vitamin D levels (25(OH)D<25 nmol/l) were 
found in 18% of new mothers and in 38% of their 
newborns [17]. 
 
Gestational vitamin D concentration is considered 
important for the development of the immune system. 
The vitamin D acts as an immunomodulator by 
inhibiting the proliferation of the T cells, shifting the T-
cell population toward noninflammatory T helper 2 
(Th2) and T-regulatory cells, and suppressing the 
transcription of genes encoding key Th1 pro-
inflammatory cytokines [18]. Genes associated with 
many autoimmune diseases are enriched for vitamin D 
receptor-binding sites [19-21], suggesting that the 
combined effect of vitamin D deficiency, genetic 




























Figure 5. Odds ratios  for men and women with neovascular AMD being born  in different months  in  Italy between
1925 and 1944 (n = 45845) with 95% confidence intervals. 
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may concur in the pathogenesis. Seasonal changes in 
immune function are also mediated by the pineal 
hormone melatonin, which has a proinflammatory 
action [31], by increasing the release of Th1 cytokines 
[22].  
 
In animal models, gestational vitamin D deficiency 
affects brain development [23], and the myelination 
process [24], and it could have an effect on retinal cells. 
Vitamin D is involved in the pathogenesis of 
neovascular AMD, and a significant correlation has 
been found between reduced plasma vitamin D level 
and the prevalence of AMD [25-28]. A recent meta-
analysis reported a correlation between latitude, 
insolation, and the incidence of severe AMD; higher 
incidence was found in locations with insolation <3 
kWh/m2/day compared with those with insolation >3 
kWh/m2/day (P < 0.001) [29]. 
 
An effect of the month of birth has also been reported 
for ocular conditions such as myopia.  In Israel, a study 
found increased rates of moderate and severe myopia in 
people born in summer and lower rates in those born in 
winter (9% and 8.5%, and 2.2% and 2.7%, 
respectively). These differences correlated with the 
number of daylight hours, which is thought to relate to 
the melatonin level, or an imbalance in the melatonin–
dopamine relationship.[30]. Similarly, a study in the UK 
reported a 4.1% increased rate of severe myopia in 
summer–autumn and 3.6% lower rate in winter–spring. 
However, the lack of relationship between severe 
myopia and the number of daylight hours, suggested the 
influence of other season-related factors, such as the 
birth weight [31]. 
 
Studies of the effect of birth month or birth season have 
observed significant variability in birth month in the 
general population. This factor, combined with the 
inevitable heterogeneity in region of origin and year of 
birth, can lead to false-positive associations [32]. In this 
study, we included people born throughout Italy over a 
20-year period (1925–1944), thus avoiding the possible 
effect of a single year. 
 
This study has several limitations. Although season of 
birth is a well-defined variable, it is only one possible 
factor in the pathogenesis of the n-AMD. It is associated 
with various other environmental factors, such as 
meteorological factors, daily sunlight exposure, and 
alterations in air pollution and food supply, as well as 
behavioral variables, including dietary habits and 
physical activity levels. Personal factors, such as 
smoking, urban or rural residency, alimentary habits, 
and migration (inside or outside Italy) could have 
caused different levels of exposure to risk factors and 
had an effect on the development of n-AMD. 
In conclusion, this study shows that there is seasonal 
variation in the risk of developing neovascular AMD in 





In this study, all consecutive patients recorded in the 
anti-VEGF monitoring registry of the Italian Medicines 
Agency (AIFA) who received intravitreal injections of 
anti-VEGF for n-AMD between January 1, 2013 and 
July 29, 2015 were included. The system monitors the 
registration process throughout the country and 
uploading of clinical data, and allows access to data 
about reimbursement by the National Health Service 
[33,34]. 
 
The inclusion criteria were patients born in Italy and 
treated with intravitreal anti-VEGF injection for n-
AMD. Patients born outside Italy were excluded. The 
data obtained from the AIFA database for each patient 
were year and month of birth, region of birth, and sex. 
Other parameters allowing personal identification (such 
as city or date of birth, or initials of patients) were not 
provided. The drugs used for intravitreal injections of 
anti-VEGF recorded in the AIFA registry included in 
this study were pegaptanib sodium (Macugen; 
EyetechInc, Palm Beach Gardens, FL), bevacizumab 
(Avastin; Genentech Inc., South San Francisco, CA), 
ranibizumab (Lucentis; Genentech Inc.), and aflibercept 
(EYLEA; Regeneron Pharmaceuticals, Inc, Tarrytown, 
NY).  
 
From the initial cohort of patients, to ensure a sufficient 
sample size across all 12 months, as previously 
described [4], we included in the analysis only those 
consecutive years having at least 1000 individuals 
treated. For the same years, the numbers of all births in 
Italy were extracted from the Italian National Institute 
of Statistics along with information about the month of 
birth, sex, and region of birth. These data were used to 
calculate the expected number of births of people who 
would later develop AMD under the assumption that the 
birth distributions for patients and the whole population 
are equal. 
 




The n-AMD incidence rate was calculated per 100,000 
residents per year. The distribution of season of birth 
was compared between the study population (with n-
AMD) and the corresponding Italian population. We 
compared the observed number of n- AMD cases with 
the expected number of n-AMD cases in each season, 
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and we analyzed the season-specific risk of n-AMD 
compared with the other 3 seasons using the odds ratios 
(ORs) and 95% confidence intervals (CIs) and a 2 × 2 
chi-square test. Significant (P ≤ 0.05) values for a single 
season were corrected for the 4 comparisons using the 
Bonferroni correction. 
 
We also compared the observed number of n-AMD 
cases with the expected number of n-AMD cases in 
each month, and we analyzed the month-specific risk of 
n-AMD compared with the other 11 months using ORs 
and 95% CIs and a 2 × 2 chi-square test. Significant (P 
≤ 0.05) values for single months were corrected for the 
12 comparisons using the Bonferroni correction. 
 
Subgroup analyses were performed for women and 
men. We calculated 95% CIs based on the Poisson 
distribution for describing the variation in the number of 
events during a period of time.  
 
Data were analyzed using IBM SPSS Software 22 
version (IBM Corp., Armonk, NY, USA). All P-values 
were 2-sided, and P ≤ 0.05 was considered to be 
significant. 
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